Glioblastoma Clinical Trials

328 recruitingLast updated: June 17, 2026

There are 328 actively recruiting glioblastoma clinical trials across 36 countries. Studies span Phase 1, Phase 2, Not Applicable, Early Phase 1, Phase 3, Phase 4. Top locations include New York, New York, United States, Boston, Massachusetts, United States, Houston, Texas, United States. Updated daily from ClinicalTrials.gov.


Glioblastoma Trials at a Glance

328 actively recruiting trials for glioblastoma are listed on ClinicalTrialsFinder across 6 cities in 36 countries. The largest study group is Phase 1 with 120 trials, with the heaviest enrollment activity in New York, Boston, and Houston. Lead sponsors running glioblastoma studies include Mayo Clinic, M.D. Anderson Cancer Center, and Northwell Health.

Browse glioblastoma trials by phase

Treatments under study

About Glioblastoma Clinical Trials

Looking for clinical trials for Glioblastoma? There are currently 180 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Glioblastoma trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Glioblastoma clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 328 trials

Recruiting
Not Applicable

The Feasibility and Efficacy of Dose Timing (Morning vs Evening) of Temozolomide in the Treatment of Glioblastoma

Glioblastoma (GBM)IDH Wildtype Glioblastoma
Ottawa Hospital Research Institute50 enrolled2 locationsNCT06850766
Recruiting
Phase 1Phase 2

Novel Indenoisoquinolone CMYC/TOPOISOMERASE 1 Inhibitor (LMP744) in Recurrent Glioblastoma

Brain CancerGBMGlioma+12 more
National Institute of Neurological Disorders and Stroke (NINDS)40 enrolled1 locationNCT07416188
Recruiting
Not Applicable

Alpha Radiation Emitters Device (DaRT) for the Treatment of Recurrent Glioblastoma

Recurrent GlioblastomaRecurrent Gliomas
Alpha Tau Medical LTD.10 enrolled3 locationsNCT06910306
Recruiting
Early Phase 1

Dosimetry, Safety, and Efficacy Study of [177Lu]Lu-XT771 in Patients With Recurrent Glioblastoma

Recurrent Glioblastoma, IDH-WildtypeGlioblastoma (GBM)Recurrent Glioblastoma+1 more
Beijing Tiantan Hospital5 enrolled2 locationsNCT07648823
Recruiting

Collection of Blood and Urine Samples in Patients Receiving Radiation Therapy for Glioblastoma Multiforme

Glioblastoma Multiforme
National Cancer Institute (NCI)200 enrolled1 locationNCT00083512
Recruiting
Phase 2

Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII

Central Nervous System DiseasesBrain CancerGlioblastoma Multiforme (GBM)+4 more
Black Diamond Therapeutics, Inc.162 enrolled13 locationsNCT07326566
Recruiting
Phase 1Phase 2

A Study of Debio 0123 in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Debio 0123 in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed Glioblastoma

Glioblastoma IDH (Isocitrate Dehydrogenase) WildtypeAstrocytoma, Grade III
Debiopharm International SA116 enrolled16 locationsNCT05765812
Recruiting
Not Applicable

Music Therapy in Newly Diagnosed Glioblastoma After Chemoradiation Therapy (MELODY-GBM)

Glioblastoma (GBM)
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins35 enrolled1 locationNCT07375992
Recruiting
Phase 2

Adjuvant Temozolomide ± 5-Aminolevulinic Acid + Low Intensity Diffuse Ultrasound Sonodynamic Therapy System for Newly Diagnosed Glioblastoma

GlioblastomaGBM
Alpheus Medical, Inc.103 enrolled10 locationsNCT07225621
Recruiting
Phase 1Phase 2

Study of an AAV Mediated Dual-Payload Gene Therapy in Patients With High Grade Glioma

Glioblastoma (GBM)Recurrent GlioblastomaNewly Diagnosed Glioblastoma+1 more
Trogenix ltd68 enrolled2 locationsNCT07346144
Recruiting
Phase 1

Locoregional Administration of Genetically Engineered Cells (EGFR/IL13Rα2 Pool-CAR T Cells) for the Treatment of Recurrent or Progressive High-Grade Gliomas

Recurrent Astrocytoma, IDH-Mutant, Grade 4Recurrent Glioblastoma, IDH-Wildtype
City of Hope Medical Center24 enrolled1 locationNCT07544992
Recruiting
Phase 2Phase 3

A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma

Glioblastoma
Global Coalition for Adaptive Research2,250 enrolled63 locationsNCT03970447
Recruiting
Phase 1

Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma

Astrocytoma, IDH-Mutant, Grade 2Recurrent Adult Diffuse Hemispheric Glioma, H3 G34-MutantRecurrent Adult Diffuse Midline Glioma, H3 K27-Mutant+4 more
National Cancer Institute (NCI)30 enrolled42 locationsNCT06860594
Recruiting
Phase 1Phase 2

Atezolizumab and Cabozantinib for the Treatment of Recurrent Glioblastoma

Recurrent GlioblastomaRecurrent Gliosarcoma
M.D. Anderson Cancer Center6 enrolled1 locationNCT05039281
Recruiting
Phase 1

Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors

Breast CancerCervical CancerColon Cancer+4 more
Orano Med Theranostics, SAS48 enrolled8 locationsNCT05283330
Recruiting
Phase 1Phase 2

New Adjuvant Vaccine in Glioblastoma, a Phase 1/2a Study

Newly Diagnosed Glioblastoma
Assistance Publique - Hôpitaux de Paris35 enrolled3 locationsNCT06622434
Recruiting
Phase 1

Study of ABBV-637 or ABBV-155 With ERAS-801 for People With Glioblastoma

GlioblastomaGliosarcoma
Memorial Sloan Kettering Cancer Center60 enrolled11 locationsNCT06934889
Recruiting

Targeted Pediatric High-Grade Glioma Therapy

Metastatic Brain TumorGlioblastomaGlioblastoma Multiforme+6 more
Nationwide Children's Hospital350 enrolled21 locationsNCT05839379
Recruiting
Phase 1

ONC206 for Treatment of Newly Diagnosed, Recurrent Diffuse Midline Gliomas, and Other Recurrent Malignant CNS Tumors

Central Nervous System TumorGlioblastomaCNS Tumor+5 more
Sabine Mueller, MD, PhD208 enrolled7 locationsNCT04732065
Recruiting
Phase 1

A Phase 1 Safety and Dose Finding Study of GLIX1 in Adults With Recurrent or Progressive High-grade Glioma

GlioblastomaGliomaGlioblastoma Multiforme of Brain
Tetragon Biosciences Ltd30 enrolled3 locationsNCT07464925